Analystreport

CELYAD SA/ADR (NASDAQ: CYAD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors